期刊文献+

局限期小细胞肺癌三维适形放疗及同步化疗的临床研究 被引量:15

Clinical outcomes of concurrent three-dimensional conformal radiotherapy and chemotherapy for llmited-stage small cell lung cancer
原文传递
导出
摘要 目的 观察三维适形放疗(3DCRT)同步化疗对局限期小细胞肺癌(LSCLC)的疗效及毒副反应.方法 93例LSCLC患者随机分为3DCRT组(46例)和常规组(47例),均先顺铂+足叶乙甙或卡铂+足叶乙甙方案化疗1周期,再同步放化疗,然后继续化疗,共4-6周期.达完全缓解者给予脑预防照射30 Gy分10次.常规组按常规设野,3DCRT组只包括原发灶、转移淋巴结及邻近一站淋巴引流区.放疗2 Gy/次,5次/周,共60~64 Gy.结果 3DCRT组和常规组随访率分别为100%和100%,随访时间满1、2、3年者分别为36和34、16和14、7和8例.3DCRT组和常规组完全缓解率分别为52%和47%,有效率分别为89%和85%(χ^20.34,P=0.759).3DCRT组和常规组1、2,3年生存率分别为78%和72%、35%和30%、15%和17%(χ^2=0.18,P=0.92),中位生存期分别为23.2和22.8个月.三维适形放疗组1+2级早期放射性肺和食管反应、1+2、3级晚期放射性肺损伤均轻于常规放疗组,两组均无3、4级早期肺和食管反应,以及4级晚期肺损伤;1+2、3、4级急性骨髓抑制两组相似.结论 3DCRT同步化疗用于LSCLC治疗可获得满意的近、远期疗效,毒副反应小,有较高的临床可行性. Objective To evaluate therapeutic effects and complications of concurrent three- dimensional conformal radiotherapy (3DCRT) and chemotherapy in patients with limited-stage small cell lung cancer (LSCLC). Methods From June 2000 to August 2005, 93 histologically proved I^CLC patients were randomized into two groups : 3 DCRT group ( n = 46) and conventional group ( n = 47 ). In both groups, patients received one cycle chemotherapy, followed by concurrent chemoradiotherapy and then received consolidate chemotherapy. Chemotherapy was four to six cycles of PE regimen. Conventional irradiation field was setup in conventional group, while in 3DCRT group clinical target volume (CTV) only involved visible tumor and adjacent lymphatic region. Radiotherapy was delivered at 2 Gy per fraction, 5 fractions per week to a median total dose of 60 - 64 Gy. Those who achieved a complete response were treated with prophylactic cranial irradiation (PCI) with 30 Cry in 10 fractions. Results The follow-up rate was 100% in both groups. The number of patients completed 1-, 2-and 3-year follow-up were 36, 34 and 16 in 3DCRT group, 14, 7 and 8 in conventional group, respectively. The complete and overall response rate were 52% and 89% in 3DCRT group, while 47% and 85% in conventional group, respectively. The 1-, 2- and 3-year survival rates were 78% , 35% and 15% in 3DCRT group, 72% , 30% and 17% in conventional group, respectively. The median survival time was 23.2 and 22. 8 months, re,pectively. There was no statistical difference in short-term ( χ^2 = 0. 34, P = 0. 759 ) and long-term outcomes ( χ^2 = 0. 18, P = 0. 92 ). In 3DCRT group, the incidence of grade 1 + 2 acute radiation pneumonitis and esophagitis, grade 1 + 2 and grade 3 chronic radiation pneumonitis were lower than those in conventional group. There was no grade 3 or 4 acute radiation pneumonitis or esophagitis, or grade 4 chronic radiation pneumonitis in both groups. There was no difference in grade 1 + 2, grade 3 or grade 4 acute myelo-suppression between the two groups. Conclusions In the treatment of LSCLC, concurrent 3DCRT and chemotherapy can achieve satisfactory short-term and long-term outcomes with acceptable complications.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2010年第3期205-208,共4页 Chinese Journal of Radiation Oncology
基金 国家自然科学基金项目(30710103088)
关键词 小细胞肺癌/放化疗法 放化疗法 同步 放射疗法 三维适形 预后 Carcinoma, small cell lung/radiochemotherapy Radiochemotherapy, concurrent Radiotherapy,there-dimensional conformal Prognosis
  • 相关文献

参考文献11

  • 1于金明,任瑞美,袁明智,尹勇,岳金波.早期非小细胞肺癌三维适形放疗剂量分割研究[J].中华放射肿瘤学杂志,2005,14(3):158-161. 被引量:30
  • 2Socinski MA,Bngart JA.Limited-stage small-cell lung cancer:the current status of combined-modality therapy.J Clin Oncol,2007,25:4137-4145.
  • 3Ettinger DS,Berkey BA,Abrams RA,et al.Study of paclitaxel,etoposide and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer:a radiation therapy oncology group 9609 phase Ⅱ study.J Clin Oncol,2005,23:4991-4998.
  • 4Erridge SC,Murray N.Thoracic radiotherapy for limited-stage small cell lung cancer:issues of timing,volume,doses,and fraction.Semin Oncol,2003,30:26-37.
  • 5王颖杰,王绿化,陈东福,周宗玫,欧广飞,梁军,张可,殷蔚伯.小细胞肺癌的三维适形放射治疗[J].中华肿瘤杂志,2005,27(9):570-572. 被引量:12
  • 6Mohan A,Goyal A,Singh P,et al.Survival in small cell lung cancer in India:prognostic utility of clinical features,laboratory parameters and response to treatment.Indian J Cancer,2006,43:67-74.
  • 7De Ruysscher D,Bremer BH,Koppe F,et al.Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer:a phase Ⅱ trial.Radiother Oncol,2006,80:307-312.
  • 8Bass P,Belderbos JS,Senan S,et al.Concurrent chemotherapy (carboplatin,paclitaxel,etoposide) and involved-field radiotherapy in limited stage small cell lung cancer:a Dutch multicenter phase Ⅱ study.Br J Cancer,2006,94:625-630.
  • 9Chen GY,Jiang GL,Wang LJ,et al.Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer:a clinical phase Ⅱ trial.Int J Radiat Oncol Biol Phys,2005,61:70-75.
  • 10Komaki R,Swann RS,Ettinger DS,et al.Phase Ⅰ study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small cell lung cancer:report of radiation therapy oncolngy group (RTOG) protocol 97-12.Int J Radiat Oncol Biol Phys,2005,62:342-350.

二级参考文献23

  • 1Cheung PC, Yeung LT, Basrur V, et al. Accelerated hypofractionation for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys,2002,54:1014-1023.
  • 2Slotman B J, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small-cell lung cancer. Radiother Oncol, 1996, 41:41-44.
  • 3沈瑜.放射治疗中的时间、剂量和分次[A].见:沈瑜 糜福顺 主编.肿瘤放射生物学[C].北京:中国医药科技出版社,2001.200-219.
  • 4Mehta M, Scri mger R, Mackie R, et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys,2001,49:23-33.
  • 5Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys, 2000, 46: 516-517.
  • 6Martel MK, Ten-Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of nonsmall cell lung cancer patients. Lung Cancer, 1999,24:31-37.
  • 7Malissard L, Nguyen TD, Jung GM, et al. Localized adenocarcinoma of the lung: a retrospective study of 186 non-metastatic patients from the French Federation of Cancer Institutes-the Radiotherapy Cooperative Group. Int J Radiat Oncol Biol Phys, 1991,21:369-373.
  • 8Bradley JD, Wahab S, Lockett MA, et al. Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys, 2003,56: 342-347.
  • 9Robertson JM, Ten-Haken RK, Hazuka MB, et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys, 1997,37:1079-1085.
  • 10Erridge SC, Murray N .Thoracic radiotherapy for limited-stage small cell lung cancer: issues of timing,volumes,doses,and fractionation.Seminars In Oncol,2003,30:26-37.

共引文献40

同被引文献133

引证文献15

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部